高盛：石药集团_与跨国公司达成的首个海外 BD 交易；授权代谢药物.

8 October 2024 | 6:23AM HKT CSPC Pharma (1093.HK): First overseas BD deal with MNC; Licensing-out a metabolism drug Licensing-out a pre-clinical metabolism asset to AstraZeneca (AZ): CSPC announced plans to license out the global rights of YS2302018, a lipoprotein(a) (Lpa) small molecule inhibitor in pre-clinical stage and any product that contains YS2302018, which could refer to combination therapy, to AstraZeneca for: 1) an upfront payment of US$100mn, which we see as quite meaningful for a pre-clinical a ...